Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

Thomas Rauch; Ulrike Graefe-Mody; Carolyn F Deacon; Arne Ring; Jens Juul Holst; Hans-Juergen Woerle; Klaus A Dugi; Tim Heise

doi:10.1007/s13300-012-0010-y

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

Thomas Rauch, Ulrike Graefe-Mody, Carolyn F Deacon, Arne Ring, Jens Juul Holst, Hans-Juergen Woerle, Klaus A Dugi, Tim Heise

Endocrinology and Metabolism

Research output: Contribution to journal › Journal article › Research › peer-review

46 Citations (Scopus)

Abstract

Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.

Original language	English
Journal	Diabetes Therapy
Volume	3
Issue number	1
Pages (from-to)	10
ISSN	1869-6953
DOIs	https://doi.org/10.1007/s13300-012-0010-y
Publication status	Published - Nov 2012

Access to Document

10.1007/s13300-012-0010-y

Cite this

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. / Rauch, Thomas; Graefe-Mody, Ulrike; Deacon, Carolyn F; Ring, Arne; Holst, Jens Juul; Woerle, Hans-Juergen; Dugi, Klaus A; Heise, Tim.

In: Diabetes Therapy, Vol. 3, No. 1, 11.2012, p. 10.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{c3292bcbdbe44b9193462a04737ba585,

title = "Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus",

abstract = "Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.",

author = "Thomas Rauch and Ulrike Graefe-Mody and Deacon, {Carolyn F} and Arne Ring and Holst, {Jens Juul} and Hans-Juergen Woerle and Dugi, {Klaus A} and Tim Heise",

year = "2012",

month = nov,

doi = "10.1007/s13300-012-0010-y",

language = "English",

volume = "3",

pages = "10",

journal = "Diabetes Therapy",

issn = "1869-6953",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

AU - Rauch, Thomas

AU - Graefe-Mody, Ulrike

AU - Deacon, Carolyn F

AU - Ring, Arne

AU - Holst, Jens Juul

AU - Woerle, Hans-Juergen

AU - Dugi, Klaus A

AU - Heise, Tim

PY - 2012/11

Y1 - 2012/11

N2 - Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.

AB - Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.

U2 - 10.1007/s13300-012-0010-y

DO - 10.1007/s13300-012-0010-y

M3 - Journal article

C2 - 22986920

VL - 3

SP - 10

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 1

ER -